Vermillion (VRML) Lifted to Buy at ValuEngine

ValuEngine upgraded shares of Vermillion (NASDAQ:VRML) from a hold rating to a buy rating in a research report report published on Wednesday morning, ValuEngine reports.

VRML remained flat at $$1.23 on Wednesday. The company had a trading volume of 71,682 shares, compared to its average volume of 65,516. Vermillion has a 12-month low of $0.27 and a 12-month high of $1.57. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.27 and a quick ratio of 3.61.

Vermillion (NASDAQ:VRML) last posted its earnings results on Thursday, March 28th. The company reported ($0.04) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Vermillion had a negative return on equity of 150.34% and a negative net margin of 381.57%. The firm had revenue of $0.92 million during the quarter.

In related news, Director David Schreiber sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $1.00, for a total value of $30,000.00. Following the completion of the sale, the director now directly owns 137,405 shares in the company, valued at approximately $137,405. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.40% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Birchview Capital LP increased its position in Vermillion by 0.4% in the 1st quarter. Birchview Capital LP now owns 2,121,933 shares of the company’s stock worth $2,440,000 after buying an additional 8,000 shares during the period. Morgan Stanley increased its position in Vermillion by 390.2% in the 1st quarter. Morgan Stanley now owns 25,000 shares of the company’s stock worth $29,000 after buying an additional 19,900 shares during the period. Greenwich Wealth Management LLC increased its position in Vermillion by 11.3% in the 4th quarter. Greenwich Wealth Management LLC now owns 241,121 shares of the company’s stock worth $72,000 after buying an additional 24,500 shares during the period. Magnus Financial Group LLC bought a new position in Vermillion in the 1st quarter worth approximately $35,000. Finally, B. Riley Wealth Management Inc. increased its position in Vermillion by 38.4% in the 4th quarter. B. Riley Wealth Management Inc. now owns 182,245 shares of the company’s stock worth $55,000 after buying an additional 50,545 shares during the period. Hedge funds and other institutional investors own 20.92% of the company’s stock.

About Vermillion

Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.

See Also: What is the Fibonacci sequence?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.